Nationwide Zenzedi recall announced due to mislabeled packaging

Zenzedi recall overview: 

• Who: Azurity Pharmaceuticals is recalling one lot of Zenzedi CII 30-milligram tablets. 
• Why: A Nebraska pharmacist found carbinoxamine maleate antihistamine tablets inside a bottle instead of Zenzedi.
• Where: The narcolepsy tablet recall is valid across the United States.

Azurity Pharmaceuticals has issued a recall of one lot of its Zenzedi CII 30-milligram narcolepsy tablet after a Nebraska pharmacist found carbinoxamine maleate antihistamine tablets inside a Zenzedi bottle.

The pill mix-up could lead to the under-treatment of narcolepsy symptoms — which Zenzedi is used to treat — and functional impairment along with an increased risk of accidents or injury, the narcolepsy tablet recall says.

The recall includes lot F230169A of Zenzedi with an expiration date of 2025-06, which shipped to wholesalers between Aug. 23 and Nov. 29, 2023.

Zenzedi is a light-yellow hexagonal tablet marked “30” on one side and “MIA” on the other, distributed in a white bottle with black writing and “30 mg” highlighted yellow. The carbinoxamine maleate tablets are white round tablets with imprints of “GL” on one side and “211” on the other.

Zenzedi sent recall notices to wholesale distributors Jan. 4.

Stop taking pills and return to place of purchase, Zenzedi recall advises

Azurity Pharmaceuticals says it so far has not received any reports of serious adverse effects related to the narcolepsy tablet recall. The company is not facing legal action over the recall, but Top Class Actions follows recalls closely as they sometimes lead to class action lawsuits.

Azurity asked consumers to stop using the pills and return them to the place of purchase.

Inmar Intelligence will facilitate the recall and can be reached at 877-804-2069 between 9 a.m. and 5 p.m. ET Monday through Friday. Wholesalers and retailers must mail all returns to Inmar at 3845 Grand Lakes Way, Grand Prairie, TX 75050. Reports of adverse effects can be sent to Azurity at [email protected].

Pharmaceutical company KVK-Tech initiated a voluntary nationwide recall in October for one batch of its betaxolol tablets as a precautionary measure after the company found a single oxycodone HCI tablet in its packaging line. 

Are you affected by the Zenzedi recall? Let us know in the comments. 

Read About More Class Action Lawsuits & Class Action Settlements:

• Johnson & Johnson to pay $150M in Washington opioid settlement
• Robitussin Honey CF Max recalled over microbial contamination
• Generic drug makers to pay combined $45M in settlements to end price-fixing litigation
• Walgreens class action claims retailer sells unsafe OTC UTI drug